Literature DB >> 10525402

Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate.

F J Hoedemaeker1, G Siegal, S M Roe, P C Driscoll, J P Abrahams.   

Abstract

The binding properties of Src homology-2 (SH2) domains to phosphotyrosine (pY)-containing peptides have been studied in recent years with the elucidation of a large number of crystal and solution structures. Taken together, these structures suggest a general mode of binding of pY-containing peptides, explain the specificities of different SH2 domains, and may be used to design inhibitors of pY binding by SH2 domain-containing proteins. We now report the crystal structure to 1.8 A resolution of the C-terminal SH2 domain (C-SH2) of the P85alpha regulatory subunit of phosphoinositide 3-kinase (PI3 K). Surprisingly, the carboxylate group of Asp2 from a neighbouring molecule occupies the phosphotyrosine binding site and interacts with Arg18 (alphaA2) and Arg36 (betaB5), in a similar manner to the phosphotyrosine-protein interactions seen in structures of other SH2 domains complexed with pY peptides. It is the first example of a non-phosphate-containing, non-aromatic mimetic of phosphotyrosine binding to SH2 domains, and this could have implications for the design of substrate analogues and inhibitors. Overall, the crystal structure closely resembles the solution structure, but a number of loops which demonstrate mobility in solution are well defined by the crystal packing. C-SH2 has adopted a binding conformation reminiscent of the ligand bound N-terminal SH2 domain of PI3K, apparently induced by the substrate mimicking of a neighbouring molecule in the crystal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525402     DOI: 10.1006/jmbi.1999.3111

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

1.  Combinatorial Domain Hunting: An effective approach for the identification of soluble protein domains adaptable to high-throughput applications.

Authors:  Stefanie Reich; Loretto H Puckey; Caroline L Cheetham; Richard Harris; Ammar A E Ali; Uma Bhattacharyya; Kate Maclagan; Keith A Powell; Chrisostomos Prodromou; Laurence H Pearl; Paul C Driscoll; Renos Savva
Journal:  Protein Sci       Date:  2006-10       Impact factor: 6.725

2.  Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.

Authors:  Haiyan Wu; S Chandra Shekar; Rory J Flinn; Mirvat El-Sibai; Bijay S Jaiswal; K Ilker Sen; Vasantharajan Janakiraman; Somasekar Seshagiri; Gary J Gerfen; Mark E Girvin; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

3.  Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer.

Authors:  Jaclyn LoPiccolo; Seung Joong Kim; Yi Shi; Bin Wu; Haiyan Wu; Brian T Chait; Robert H Singer; Andrej Sali; Michael Brenowitz; Anne R Bresnick; Jonathan M Backer
Journal:  J Biol Chem       Date:  2015-10-16       Impact factor: 5.157

4.  p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation.

Authors:  William C Comb; Jessica E Hutti; Patricia Cogswell; Lewis C Cantley; Albert S Baldwin
Journal:  Mol Cell       Date:  2012-02-16       Impact factor: 17.970

Review 5.  The regulation of class IA PI 3-kinases by inter-subunit interactions.

Authors:  Jonathan M Backer
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

6.  Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.

Authors:  Xuxiao Zhang; Oscar Vadas; Olga Perisic; Karen E Anderson; Jonathan Clark; Phillip T Hawkins; Len R Stephens; Roger L Williams
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

7.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 8.  Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Authors:  Sandra B Gabelli; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Biochim Biophys Acta       Date:  2009-12-02

9.  Solution structure of the human Grb14-SH2 domain and comparison with the structures of the human Grb7-SH2/erbB2 peptide complex and human Grb10-SH2 domain.

Authors:  Paul J Scharf; Jill Witney; Roger Daly; Barbara A Lyons
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

10.  Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).

Authors:  John E Burke; Roger L Williams
Journal:  Adv Biol Regul       Date:  2012-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.